- Home
- INTS vs DKI Comparison
INTS vs DKI Comparison
Compare INTS & DKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- DKI
- Stock Information
- Founded
- INTS 2012
- DKI 2018
- Country
- INTS United States
- DKI Hong Kong
- Employees
- INTS N/A
- DKI N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- DKI
- Sector
- INTS Health Care
- DKI
- Exchange
- INTS Nasdaq
- DKI Nasdaq
- Market Cap
- INTS 12.2M
- DKI 11.9M
- IPO Year
- INTS 2023
- DKI 2025
- Fundamental
- Price
- INTS $0.42
- DKI $0.40
- Analyst Decision
- INTS Strong Buy
- DKI
- Analyst Count
- INTS 4
- DKI 0
- Target Price
- INTS $4.50
- DKI N/A
- AVG Volume (30 Days)
- INTS 87.5M
- DKI 217.6K
- Earning Date
- INTS 11-06-2025
- DKI 12-05-2025
- Dividend Yield
- INTS N/A
- DKI N/A
- EPS Growth
- INTS N/A
- DKI N/A
- EPS
- INTS N/A
- DKI 26.19
- Revenue
- INTS N/A
- DKI $10,204,329.00
- Revenue This Year
- INTS N/A
- DKI N/A
- Revenue Next Year
- INTS N/A
- DKI N/A
- P/E Ratio
- INTS N/A
- DKI $0.01
- Revenue Growth
- INTS N/A
- DKI 100.46
- 52 Week Low
- INTS $0.19
- DKI $0.37
- 52 Week High
- INTS $3.18
- DKI $15.00
- Technical
- Relative Strength Index (RSI)
- INTS 50.05
- DKI N/A
- Support Level
- INTS $0.38
- DKI N/A
- Resistance Level
- INTS $0.50
- DKI N/A
- Average True Range (ATR)
- INTS 0.07
- DKI 0.00
- MACD
- INTS -0.02
- DKI 0.00
- Stochastic Oscillator
- INTS 18.75
- DKI 0.00
About INTS Intensity Therapeutics Inc.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About DKI DarkIris Inc. Class A Ordinary Shares
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.